Welcome to our dedicated page for Apyx Medical SEC filings (Ticker: APYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Apyx Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Apyx Medical's regulatory disclosures and financial reporting.
Vizirgianakis Stavros G. reported acquisition or exercise transactions in this Form 4 filing.
Apyx Medical Corp director Stavros G. Vizirgianakis received a grant of 450,000 restricted stock units (RSUs). The award was granted at no cash cost per unit and is compensation rather than an open-market purchase.
According to the vesting schedule, 150,000 RSUs vest on June 11, 2026, 150,000 begin vesting on the first anniversary of that date and vest ratably over the following twelve months, and the remaining 150,000 follow the same ratable schedule starting on the second anniversary. After this grant, Vizirgianakis directly holds 2,196,191 shares or share-equivalents reported in this filing.
Apyx Medical Corp disclosed that Chief Executive Officer Charles D. Goodwin II received a grant of stock options for 213,948 shares of common stock. The options have an exercise price of $4.65 per share, vest ratably over 36 months, and become fully exercisable on the third anniversary of the grant date.
Apyx Medical Corp reported that Chief Operating Officer Shawn David Roman received a grant of stock options on Common Stock. The award covers 88,044 underlying shares with an exercise price of $4.65 per share and expires on June 11, 2036.
The options were granted as compensation and will vest ratably over 36 months, becoming fully vested and exercisable on the third anniversary of the grant date. Following this award, Roman holds 88,044 stock options directly, with no open-market share purchases or sales disclosed in this filing.
Apyx Medical Corp director Minnie Baylor-Henry received a compensatory stock option grant for 50,000 shares of common stock on June 11, 2026. The option has an exercise price of $4.65 per share and expires on June 11, 2036.
The option vests ratably over a twelve-month period and becomes fully vested and exercisable on the first anniversary of the grant date. Following this award, the filing shows 50,000 derivative securities (options) held directly.
Apyx Medical Corp director Lawrence Waldman received a grant of stock options as compensation. He was awarded options to buy 50,000 shares of common stock at an exercise price of $4.6500 per share, expiring on June 11, 2036. According to the terms, the option vests ratably over a 12‑month period and becomes fully vested and fully exercisable on the first anniversary of the grant date. Following this award, Waldman holds 50,000 stock options directly under this grant.
Apyx Medical Corp reported that Chief Financial Officer Matthew C. Hill received a grant of stock options as part of his compensation. The award covers 132,066 options to buy common stock at an exercise price of $4.65 per share, expiring on June 11, 2036. According to the disclosure, these options vest ratably over a thirty-six month period and become fully vested and exercisable on the third anniversary of the grant date. Following this grant, Hill holds 132,066 stock options directly, and the filing shows no open-market purchases or sales.
Apyx Medical Corp reported that Sr. V.P. of Operations Moshe Citronowicz received a grant of stock options. The award covers 63,392 options to buy common stock at an exercise price of $4.65 per share, expiring on June 11, 2036.
According to the disclosure, these options were granted at no cost and will vest ratably over 36 months, becoming fully vested and exercisable on the third anniversary of the grant date. Following this grant, the filing shows beneficial ownership of 63,392 derivative securities directly held as options.
Apyx Medical Corporation filed an 8-K to highlight new clinical data supporting its minimally invasive technologies for treating cellulite and skin laxity. The study, published in Aesthetic Surgery Journal Open Forum, evaluated a single-session combination treatment using Avéli for targeted subcision and Renuvion for controlled helium plasma radiofrequency tightening.
The prospective investigator-initiated study treated 22 patients and reported progressive improvement over time, with visible reductions in cellulite and, in a subset of patients, increased collagen and elastin levels through 180 days after treatment. These results add to the company’s evidence base for its Renuvion and AYON body contouring platforms, which are already backed by more than 90 clinical documents.
Apyx Medical Corporation filed an 8-K to highlight a new retrospective, investigator-initiated clinical publication evaluating its Renuvion® technology used with liposuction. The 113-patient study in Plastic and Reconstructive Surgery – Global Open found that adding helium plasma radiofrequency (Renuvion) after liposuction was associated with higher patient-reported satisfaction with abdominal appearance and excess skin, lower abdominoplasty and surgical revision rates, and complication rates comparable to conventional power-assisted liposuction alone.
The company notes this study adds to a body of more than 90 clinical documents supporting Renuvion and J-Plasma®. It also reiterates that its AYON Body Contouring System™ is an FDA-cleared, surgeon-designed platform integrating fat removal, contouring and Renuvion-based tissue contraction, and that an additional 510(k) for AYON label expansion to include power liposuction was filed in October 2025.
Apyx Medical Corporation reported that it has received expanded FDA 510(k) clearance for its AYON Body Contouring System, adding a power liposuction capability. This advanced liposuction uses a reciprocating cannula designed to improve fat removal efficiency and reduce surgeon effort and operating room time.
The company plans a limited commercial launch of the new power liposuction function to work closely with early adopters, refine training, and optimize utilization before scaling broader commercialization. AYON is described as an all-in-one, surgeon-designed body contouring platform that integrates fat removal, contouring, tissue contraction, and electrosurgical capabilities.